Jeffry Weinhuff

Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY.

Cowen & Co. LLC is a SEC-registered broker/dealer headquartered in New York City. The firm was founded in 2004 and is a subsidiary of Cowen Holdings, Inc., ultimately owned by The Toronto-Dominion Bank (TSE: TD) in Canada. Cowen & Co. offers industry-focused investment banking for growth-oriented companies, domain knowledge-driven research and a sales and trading platform for institutional investors. Their institutional sales and trading business serves both equity and fixed-income clients. Sales and trading execution platform is structured around the following key verticals: (1) healthcare (2) technology, telecommunications and media (TMT) (3) REITs and financials (4) aerospace and defense (5) consumer and (6) alternative energy.

AcuFocus, Inc. develops KAMRA inlay for the treatment of presbyopia. Its KAMRA inlay is an intra-corneal inlay designed to create a small aperture effect, allowing the eye to see near and intermediate objects more clearly. The company was founded in 2001 and is headquartered in Irvine, CA.

Founded in 2004, TD Securities (USA) LLC is a broker/dealer located in New York City with additional offices in Toronto, Montreal, Calgary, Vancouver, London, Singapore, Tokyo and Sydney. The firm is a subsidiary of Toronto Dominion Holdings (USA), Inc. and their ultimate parent is Toronto-Dominion Bank (NYSE: TD). TD Securities (USA) provides a wide range of capital market products and services to corporate, government and institutional clients in five areas of finance including: investment banking, debt capital markets, institutional equities, foreign exchange and money markets. Their services include the underwriting and distribution of new debt and equity issues, providing advice on strategic acquisitions and divestitures and executing daily trading and investment needs. The equity group provides research coverage of media and communications, technology, financial services, oil and gas, mining and metals, industrial products, forest products, technology, utilities and power, real estate, biotechnology, consumer products and merchandising and quantitative analysis strategy. The fixed-income group provides a full range of underwriting sales and trading products for Canadian, U.S. and European debt issuers and investors.

ForSight VISION5, Inc. develops ocular drug delivery technologies and device solutions for ophthalmic diseases. It engages in the development of non-invasive products to replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. Its lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to continually receive their medication. The company was founded by Eugene de Juan Jr., J. Andrew Corley and K. Angela Macfarlane in 2010 and is headquartered in Madison, NJ.

Kurobe Pharmaceuticals, Inc. manufactures pharmaceuticals.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA.

Alcon Laboratories, Inc. develops and manufactures ophthalmic pharmaceutical products. The firm offers over-the-counter eye care products, medical devices, equipment, ophthalmic drugs, surgical instruments, needles, and sutures for microsurgery and disposable drapes. The company was founded by Robert Alexander and William Conner in 1945 and is headquartered in Fort Worth, TX.

Neurotech Pharmaceuticals, Inc. designs and develops therapeutic systems for retinal diseases. The company was founded in 1995 and is headquartered in Cumberland, RI.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel.

eyeonics, Inc. designs, develops, manufactures and sells premium intraocular lenses. Its lenses are implantable devices that replace the natural lens in the human eye, typically after the natural lens has developed cataracts that can significantly impair vision. The firm's products are designed to both replace a cataractous lens and correct a refractive error. The company was founded by Andrew J. Corley and Stuart J. Cumming in 1998 and is headquartered in Aliso Viejo, CA.

The International Intra-Ocular Implant Club is a research organization that focuses on the field of intraocular lens implantation.

OCTANe connects people and ideas with capital and resources for technology growth in Orange County. It stimulates technology job growth and wealth creation; helps entrepreneurs turn ideas into successful businesses; helps companies connect with funding and growth resources; helps senior executives access intelligence, new technologies, and talent; helps develop technology business leaders; and creates a forum for technology company leaders to have an impact on the future. The company offers LaunchPad, a pro-bono accelerator for startup companies in the technology, life science, and clean tech industries. The company was founded in 2002 and is headquartered in Aliso Viejo, CA.

AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA.

Private Medical Equity Inc (Private Medical Equity) is a private equity and venture capital firm founded by Ian Ianchulev in 1900. The firm is headquartered in San Francisco, California.

CorneaGen, Inc. engages in the provision of cornea care services. It offers precision cut corneal tissue, Descemet’s Membrane Endothelial Keratoplasty, and Descemet’s Stripping Automated Endothelial Keratoplasty. The firm's products include EndoSerter, Geuder Glass Cannula, and Donor Trephine Punch. The company was founded in 2016 and is headquartered in Seattle, WA.

Aviana Molecular Technologies LLC develops technologies for point of care diagnostic of infections. It develops a miniaturized biosensor capable of attaching to a smartphone or smart device through Bluetooth or other wireless connections. The company's diagnostic system is a diagnostic platform that can accurately, detect a target infectious disease, biomarkers or proteins in both clinical and scientific research settings. Its platform uses the latest developments in cellular communications, semiconductor electronics, micro-fluidics and manufacturing methods to create a unique point-of-care diagnostic platform to detect biomarkers or infections. The company was founded by Vanaja Ragavan in 2008 and is headquartered in Orlando, FL.

Flying L Management LLC (Flying L Management) is a venture capital firm founded in 2016. The firm is headquartered in Newport beach, California.

AEye Technologies, Inc. engages in the development of vision hardware, software and algorithms that act as the eyes and visual cortex of autonomous vehicles. It specializes in computer vision, autonomous driving, robotic vision, autonomous vehicles, lidar, sensor fusion, and three dimensional mapping. The company was founded by Luis Dussan, Ranson Wuller, Barry Behnken, and Jordan Greene in 2013 and is headquartered in Dublin, CA.

IanTech, Inc. develops ophthalmic devices for cataract surgery. Its products include miLoop, miPhaco, miMissions, and miResources. The company was founded by Luke Clauson and Sean Ianchulev and is headquartered in Reno, NV.

Sydnexis, Inc. engages in the production of ophthalmic pharmaceutical products. The company was founded by Gregory Isaac Ostrow in 2014 and is headquartered in San Diego, CA.

Surface Ophthalmics, Inc. operates as a biopharmaceutical company. It focuses on development and commercialization of innovative therapeutics. The firm’s current drug pipeline consists of three proprietary drug candidates. Surface topical eye drop drug candidates, SURF-100 and SURF-200, utilize a patented delivery vehicle. The company is founded by Mark L. Baum and it is headquartered in San Diego, CA.

Melt Pharmaceuticals, Inc. engages in the development and commercialization of proprietary non-opioid, non-intravenous, or non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. It intends to seek regulatory approval through the FDA regulatory pathway for the proprietary, patented small-molecule product candidates. The company was founded by Mark L. Baum on April 3, 2018 and is headquartered in Brentwood, TN.

SBI JI Innovation Advisory Ltd (SBI JI Innovation Advisor) is a venture capital firm founded in 2017. The firm is headquartered in Tel Aviv-Yafo, Israel.

TherOptix, Inc. develops and manufactures drug-eluting contact lens. The company is headquartered in San Francisco, CA.

AEYE Health LLC is a digital health company that provides fully autonomous, AI-based diagnostic screening solutions for retinal imaging with results. The company is based in New York, NY. The company aims to make diagnostic screening practical, accurate, and accessible. Its screening solution for diabetic retinopathy is FDA-cleared and designed to allow primary care providers to perform diabetic eye exams in their clinics instead of referring to specialists. AEYE Health enables point-of-care screening for diabetic retinopathy to ensure that patients with diabetes are regularly screened for diabetic retinopathy. The company's comprehensive screening utilizes AI technology to diagnose or predict the development of a broad range of diseases from retinal images. The team consists of machine learning experts and leaders in ophthalmology and innovation. The company was founded by Zack Dvey-Aharon, Danny Margalit. Zack Dvey-Aharon has been the CEO since incorporation.

Neurolens, Inc. is a company that commercializes breakthrough technology to improve vision care. The company's patented contoured prism technology provides visual comfort for the nearly 65% of US adults who complain of headaches, neck/shoulder pain, and eyestrain when using digital devices, reading, or doing detail work. The company is based in Coppell, TX. Inspired by a breakthrough discovery linking optometry and neurology, Neurolens is unlocking a new dimension of vision care. The Neurolens contoured prism design helps the eyes work together comfortably, bringing the eyes into alignment to relieve painful symptoms. The technology is only available to independent eye care providers. The company was founded in 2012 by Davis Corley, and Pierre Bertrand has been the CEO of the company since 2019.

Aurion Biotech, Inc. is a clinical-stage biotech company with offices in multiple locations. Aurion Biotech has initiated clinical trials in the US in 2023. The company is based in Seattle, WA. The company's mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech has received the prestigious Prix Galien award for best start-up in biotech. The company's first candidate is an off-the-shelf, clinically validated cell therapy for corneal care, which has received regulatory approval. The company is privately held and backed by leading investors, including Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision/KKR, and Visionary Ventures. Greg Kunst has been the CEO of the company since 2021.